Publication: Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers

Publication: Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancers

04.16.2025

We are proud to share the latest scientific contribution of Alexis Denis, SVP Head of Drug Discovery and Marie Varin, Senior Scientist Medicinal Chemistry at Iktos, who have co-authored a newly published study in Cancer Letters uncovering promising therapeutic avenues for ATIP3-deficient breast cancers—an aggressive cancer subtype with limited treatment options and poor prognosis.

Follow the link to read the full publication.